NICE recommends Jetrea (Alcon/Thrombogenics) to treat Vitreomacular Traction
NICE (The National Institute for Health and Care Excellence) has given an initial recommendation to Jetrea (ocriplasmin) from Alcon/Thrombogenics,as an option for treating Vitreomacular Traction (VMT) in adults, including when associated with a macular hole of less than or equal to 400 microns and when patients have severe symptoms and an epiretinal membrane is not present. The final NICE guidance is expected in the third quarter of 2013.
NICE considered the use of Jetrea to treat Vitreomacular Traction with an epiretinal membrane,but concluded the drug was clinically not cost effective for this group of patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.